 |
| Services Home > New PSA Guidelines & Prostate Cancer |
|
Over the past 15 years, prostate-specific antigen (PSA) has established itself as the most important tumor marker in all solid tumor oncology and has become indispensable in the management of prostate cancer. Since the introduction of PSA-based screening, there has been a well-recognized stage migration such that the majority of prostate cancer cases diagnosed today are clinically localized, nonpalpable, PSA-detected tumors and pathologically organ-confined. Still, controversy surrounds the use of PSA as a routine screening tool.
A central issue in this controversy is the fact that PSA is organ-specific, not cancer-specific, and changes in serum PSA are not always caused by prostate cancer; rather, they may be due to inflammation, trauma, or benign prostatic hyperplasia (BPH). Additionally, considerable overlap exists in PSA levels among men with prostate cancer and BPH, and new data suggest that there is a substantial prevalence of prostate cancer in men with "normal" PSA (< 4.0 ng/mL). Due to questions surrounding the specificity of PSA, a number of modifications have been proposed to increase the performance of this analyte, such as age-specific PSA, PSA density, PSA velocity, and PSA isoforms. Furthermore, provocative data are accumulating that support examining the rate of change of PSA before the diagnosis of prostate cancer, at time of recurrence after primary therapy, and even at time of progression during hormone therapy or chemotherapy.
Here, we will first present the practical applications of PSA and PSA modifications in the diagnosis and management of prostate cancer and then introduce more recent developments and data with respect to PSA in prostate cancer management. |
| |
 |
Causes of Elevation
There are several major causes of increased serum PSA, including BPH, prostate cancer, prostate inflammation or infection, and prostate or perineal trauma. Although the PSA per gram of tissue is higher in malignant compared with benign prostate tissue, BPH is still the most common cause of elevated serum PSA. In addition to producing more PSA per gram of tissue, invasive prostate cancer can disrupt the prostate-blood barrier, further increasing serum PSA. In men with prior negative prostate biopsies, prostate acute and chronic inflammation is found to be more prevalent in patients with elevated serum PSA levels (> 4 ng/mL) compared with those with lower levels. Furthermore, although some have reported that free to total PSA ratios are not affected by the presence of inflammation, others have shown that these ratios are unable to distinguish chronic prostatitis from prostate cancer, as both may significantly decrease the ratio, raising the suspicion of prostate cancer.
From a practical standpoint, prostate instrumentation or "trauma" from cystoscopy, prostate biopsy, transurethral resection (TURP), vigorous digital rectal examination (DRE), or ejaculation may cause transient increases in serum PSA. In one study, men undergoing biopsy experienced a median 7.9 ng/mL increase and those undergoing TURP experienced a median of 5.9 ng/mL elevation. The median time for PSA to return to baseline following biopsy was 15-17 days and following TURP was 18 days. The changes in PSA following rigid and flexible cystoscopy were less pronounced at 0.1 and 0.5 ng/mL, respectively. Although DRE has been shown to cause transient and minimal increases in PSA, the PSA changes have been reported to have little clinical significance. Likewise, ejaculation can minimally elevate the serum PSA for approximately 48-72 hours. Taken as a whole, serum PSA levels after cystoscopy and DRE are believed to be accurate and reliable, a serum PSA level should not be obtained 48-72 hours post ejaculation, and a period of at least 4-6 weeks should elapse after a biopsy or TURP before PSA levels are measured.
Read Full Article (Free registration to Medscape required) |
| |
 |
Indox Consulting provides access to board certified physicians practicing in all specialties nationwide. Our medical professionals can review your case in a timely, cost effective fashion and support your case through trial with authoritative analysis, affidavits and compelling testimony.
Call us to discuss your case today. |
|
Back to Top >
|
|
|
Indox Consulting:
479 Church St. Suite 2
San Francisco, CA 94114
Phone: 1-415-568-7116
Email: info@indoxconsulting.com
©2005, Indox Consulting
|
|
|